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Liöge University/Belgium
In 1967, LAURITZEN proposed a dynamic test to
investigate placental steroidogenesis [7]. Intra-
venous injection of 50 mg dehydroepiandrosterone-
sulfate (DHEA-S) to pregnant women induced an
increase of urinary estriol excretion; but with
placental insufficiency this increase was absent or
reduced. Since 1973therehave been several studies
of the DHEA-S Loading Test (DLT) in which
maternal plasma levels of estrogens were deter-
mined [l, 2, 3, 4, 5, 6, 8, 12, 13, 14]. After an
intravenous injection of 50 mg of DHEA-S, Estrone
(Ei) levels increase about threefold within two to
four hours and return to baseline values eight to
twelve hours later; Estradiol (E2) levels increase
two to fivefold within the first hour and return to
initial values twelve hours later; unconjugated
estriol (E3) sometimes shows an increase of 50%
between six and twelve hours after the injection [13].
An adequate method for interpreting the DLT in
cUnicaTu.se has not yet been found. The accuracy
of the plasmatic DLT to indicate fetal risk has not
been proven with certainty. Nevertheless NAGEY
and PUPKINS [9, 11] using a mathematical repre-
sentation of a physiological model of the DHEA to
estrogen conversion System, demonstrated the
ability of DLT to indicate fetal jeopardy or/and
placental insufficiency. Using a similar model, we
have attempted to investigate the decrease of
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l Material and method
A Single DLT was performed on each of 27
pregnant women at 32—42 weeks gestation. All
the patients were under care from the beginning of
pregnancy till delivery by the Obstetrical depart-
ment of the University of Liege. There was no
fetal or neonatal death in the study. An intravenous
injection of 50 mg DHEA-S (Ro 6-6827/6: RÖCHE
S. A./Basel) was given in a single bolus at eight
o'clock in the mörning. A blood sample was collect-
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cd prior to the injection and at least flve samples
in the following three hours, the first one no more
t h an 30 minutes after the injection. Serum uncon-
jugated E2 was determined by radioimmunoassay
after extraction with etherandeluation on sephadex
LH-20 columns in a benzene-dichloromethane-
methanol System (60v-30v- l Ov). The results were
analyzed by fitting a mathematical representation
of a Physiologie model of the DHEA-S to E2
conversion System, using a Computer program.
This model is a modification of NAGEY'S [9]. It
allows the evaluation of the DHEA-S to E2 con-
version rate constant given the serum E2 con-
centrations and the time intervals after injection.
Details on biologicaJ facts and assumptions and on
the mathematical development which lead to the
establishment of the model are clearly explained
in NAGEY'S publication. Briefly, DHEA-S to E2
conversion rate constant is calculated by fitting
the following equation to the DLT data from each
patient:
where: t = time interval (min)
E2(t) = Estradiol concen trations at different
times after injection (Moles/litre)
E2(o) = Estradiol concentration before in-
jection (Moles/litre)
Qo = DHEA-S concentration change in-
duced by the DHEA-S injection =
quantity of DHEA-S injected divided
by plasma volume (Moles/litre)
















0*0 5.00000*01 1.00000*02 1.50000*02 2.00000*02
2.50000*01 7*50000*01 1.25000*02 1*75000*02 2.25000*02
E2 TOTAL - 34 COfcEZ
M D B S TOTAL * 31 25
Fig. 1. An example of the course of E2 levels (Moles/litre) given by the Computer in case n° 34 (o = DLT datas; T :
calculated points; T and o values are indentical at time 0 and 180.
E2 level scale: from 4.10'8 to 2,4.10'7 Moles/litre (i.e. 1.2000 D - 07 = 1,2.10'7)
time scale: from 0 to 225 minutes (i.e.: 1.2500 D + 02 = 1,25.10"2 = 125)
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b =rate constant of DHEA-S to E2
conversion (Min ""*)
c = rate constant of E2 clearance
Estimation of parameters is based on the least
squares method. Owingto the fact that the relation
between E2 and parameters is a non-linear one, the
problem does not admit analytical Solutions; para-
meters have been evaluated in all cases, using a
Computer program of function minimization based
on the NELDER-MEAD simplex method [10].
Fig. l. shows an example of the course of E2 levels
given by the Computer when fitting the equation
to the DLT data of a representative patient (n° 34).
The constant b, which reflects placental aromat-
ization activity, is the required parameter.
To clarify the meaning of b, it can be said that it
represents the proportion of exogenous DHEA-S
which can be converted to E2 by the placenta in
one minute.
2 Results
Tab. I gives the results of the DLTs in the 27
patients divided into six groups according to
maternal pathology or pregnancy complication
and feto-placental outcome.
Group I is the control group and comprises eight
patients who had uneventful pregnancies and
normally grown undistressed infants.
Group II comprises three cases of premature
labor without any fetal impairment.
Group III contains six cases of various pathological
situations at test time without any feto-placental
complications. Group IV includes three post-term
DLT. One fetus presented acute distress during
labor.
Group V is composed of six cases of intra-uterine
fetal growth retardation (I.U.G.R.) in which birth
weights were below the lOth percentile. Details on
pregnancy complication is given in the table.
Group VI is a case of sex4inked hydrocephaly.
Basal E2 levels (ng/ml) and DHEA-S to E2 con-
version rate constant (min"1 X l O""6) are written
for each DLT.
Tab. II presents the mean and ränge (after log-
arithmic transformation) of'basal E2 values and
of DHEA-S to E2 conversion rate constants for the
three main clinical groups: Control group (I);
Tab. U. Comparisons between group I and groups III and
V for serum E2 concentrations and for DHEA-S to E2
conversion rate constant (*: statisticaUy significant at
probability level = 0.05)
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(80-+3554) (128-»4115) (11-»260)
(°) (The means, expressed in original units, are calculated
from logarithms of the observation).
pathological pregnancy group without fetal
impairment (III) and I.U.G.R. group (V).
Statistical comparison between group I and III
and between group I and V uses the non-parametric
confidence interval method. Serum E2 concen-
trations before precursor injection are significantly
lower in both the pathological pregnancy group
and the I.U.G.R. group. DHEA-S to E2 conversion
rate constants are not significantly reduced in group
III but are markedly impaired in group V.
3 Comments
It seems probable that in the pathogenesis of fetal
risk, äs found in intra-uterine growth retardation,
the decrease of utero-placental perfusion is usually
the first event to occur. This decrease of utero-
placental blood flow occurs in various disturbances
of pregnancy but acquires clinical importance
when leading to fetal distress. It can be presumed
that the decrease of blood flow, when sufficient
to induce poor fetal growth may also lead to a
diminution of placental enzyme capacity.
This diminution cannot be demonstrated by
simple blood estrogen determination which may
be reduced by a low availability of precursors.
Many patients excrete little estrogen without
lowered placental aromatization. It appears of
first importance to evaluate the placental bio-
synthetic capacity äs an Information on fetal
health.
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The DHEA-S to E2 conversion rate constant, such
äs determined in this paper, reflects the speed of
placental aromatization of C-19 precursors to
estrogens. It may thus be considered äs a good
index of placental enzyme capacity. It is shown
that a low DHEA-S to E2 conversion rate constant
is more often associated with lowered fetal growth
which cannot be indicated by simple basal E2
determination. The low estrogen levels in fetal
impairment do not result from a diminution of
precursor availability alone but also from reduced
placental enzyme capacity.
This mathematical model is not applicable to
serum unconjugated E3 concentrations for two
reasons. First, the E3 rise after i.v. DHEA-S
injection is not always significant and occurs more
than four hours after the injection. Thus one of
\the assumptions which lead to the establishment
of the model is invalid in this case [9].
Secondly, E3 production from C-19 precursors
involves a 16-a hydroxylation which mainly occurs
in the fetus or in the maternal liver. The physiolog-
ical model considered simply äs a two compartments
model is barely suffident to describe the E2 change
during the DLT. The model should certainly be
inadequate for investigating three or more com-
partments äs for E3.
As described in this paper, DLT u sing the calculation
of the DHEA-S to E2 conversion rate constant
allows only a placental evaluation. But this eval-
uation is more sensitive because by administering
DHEA-S the unknown variable "precursor" is
excluded. We agree with LAURITZEN'S opinion [8]
that the test is not a substitute for the usual
estrogen determinations, but should rather be
complementary to them and give additional in-
formation on the eventuai repercussions of the
so called "placental insuffidency" on fetal well-
being.
Summaiy
This study attempts to investigate the decreaseof placental
aromatization of dehydroepiandrosterone-sulfate (DHEAr
S) to estrogens, in case of fetal growth retardation.
27 intravenöus DHEA-S loading tests (DLT) have been
performed in 27 pregnant women (Tab. I): There were
eight normal pregnant women with normal babies (group
I, control); six cases of various pathological situations
without fetal impairment (group III), and six cases of
intra-uterine fetal growth retardation (group V, I.U.G.R.)-
Thedose of DHEA-S was 50 mg. The parameter investigated
was the maternal serum concentration öf Estradiol (E2)
within the first three hours following the injection. The
data were analyzed by f itting a mathematical representation
of DHEA-S to £2 conversion System using a Computer
program. This mathematical model permits the calculation
of the DHEA-S to E2 conversion rate constant, which
represents the proportionof exogenous DHEA-S converted
in £2 in one minute by the placenta and thus reflects the
placental ability to aromatize €19 precursors. Table II
presents the mean and ränge of E2 baseline values and of
DHEA-S to E2 conversion rate constants for the three
defined group s. Statisticalcomparisonshows that E2 serum
concentrations before the test are lower in both patholog-
ical group ( ) and IUGR group (V) whüe DHEA-S to E2
conversion rate constant is impaired only in the IUGR
group (V). It is concluded that fetal growth retardation,
resulting from placental insufficiency, is more often
associated with a lack of placental steroidosynthesis. The
lowered estrogen excretion in case of fetal impairment
does not result from a diminution of precursor availability
alone but also from a reduced placental enzymatic capacity.
The DLT and the calculation of DHEA-S to E2 con-
version rate constant is able to indicate the enzymatic
insufficiency.
It constitutes a sensitive test for evaluating placental
disturbance.




KliniscHe Anwendung eines mathematischen Modells zur
InterpretationdesDehydroepiandrosteron-Belastungstestes
im letzten Trimester der Schwangerschaft.
In dem vorliegenden Artikel wkd die Abnahme von
Östrogen bei verzögertem Wachstum des Foeten unter
Verwendung von Dehydroepiandrosterone Sulfat (DHEA-
S) untersucht.
Es wurden 27 DHEA-S Belasturigstests (nach LAURITZEN)
durchgeführt (Tab. I). 8 Schwangerschaften waren normal,
6 pathologisch mit normalem Fötus und in weiteren 6
verlief das Wachstum des Foeten verzögert.
In allen Fällen wurden 50 mg DHEA-S injiziert und die
Zunahme an Östradiol (E2) im Plasma mehrmals inner-
halb drei Stunden nach der Einspritzung gemessen. Die
Analyse der Werte erfolgte nach einem mathematischen
Modell mit Hilfe eines Computers. Das Modell zeigt die
Biotransformation von E2 aus DHEA-S in der Plazenta.
Mit diesem Modell kann die Umwandlungskonstante
(DHEA-S in E2), das heißt das Verhältnis von DHEA-S
zu E2 errechnet werden. Sie spiegelt die Fähigkeit der
Plazenta, Cl 9-Steroide in Östrogene umzuwandeln, wieder.
Tab. II zeigt die mittleren und die Extremwerte der Blut-
östrogene und die Umwandlungskonstaiite (DHEA-S in
E2) der drei oben genannten Gruppen.
Die statistische Untersuchung zeigt, daß die Blutöstro-
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gene bei pathologischen Schwangerschaften und bei ver-
zögertem Wachstum des Poeten erniedrigt sind, während
die Umwandlungskonstante nur in Fällen von verzögertem
Wachstum des Poeten erniedrigt ist.
Hieraus läßt sich folgendes schließen: Mangelndes Foetal-
wachstum, das durch plazentare Insuffizienz verursacht
wurde, ist häufig an einen Mangel von plazentarer Steroid-
synthese gekoppelt. Die Schwäche der Steroidsynthese er-
klärt auch die erniedrigten Blutöstrogene.
Der DHEA-S-Test und die Errechnung der Umwandlungs-
konstante (DHEA-S in E2) mit Hilfe unserer mathemati-
schen Formel stellt eine gute Möglichkeit dar, das meta-
bolische Fehlverhalten in der Plazenta zu untersuchen.
Schlüsselworte: DHEA-S-Test, Östrogene, Plazentainsuffizienz, Wachstumsretardierung.
Resume
Application clinique preliminaire d'un modele mathemati-
que d'interpretation du test de surcharge au sulfate de
dehydroepiandrosterone au dernier trimestre de la
grossesse.
L'etude envisage le probleme d'une diminution de
raromatisation du sulfate de dehydroepiandrosterone
(DHEA-S) en oestrogenes dans les retards de croissance
foetale intra-uterine.
27 tests de surcharge intra-veineuse au DHEA-S ont ete
realises chez 27 gestantes parmi lesquelles (Tab. I):
huit gestantes normales ayant eu des enfants normaux
(groupe I, controle); six cas de pathologie gestationnelle
sans repercussion foetale (groupe III) et six cas de retard
de croissance intra-uterine (groupe V, I.U.G.R.). La dose
de DHEA-S etait de 50 mg dans tous les cas. Le parametre
e tu die fut la concentration seriquematernelleenoestradiol
(E2) mesuree a plusieurs reprises endeans les trois heures
suivant l'injection. Lesdonneessontanaly seessurordinateur
au moyen d'un modele mathematique cense representer
le plus exactement possible le Systeme de conversion du
DHEA-S en oestrogene dans le placenta.
Ce modele permet le calcul de la constante de conversion
du DHEA-S en E2 qui reprirente la proportion du DHEA-
S transformee en E2 en une minute. C'est un reflet de la
capacite placentaire d'aromatisation des precurseurs en
C-19 en oestrogenes.
La table II presente les valeurs moyennes et extremes des
taux de base en E2 et des constantes de conversion du
DHEA-S en E2 enregistrees dans les trois groupes definis
plus haut.
L'etude statistique montre queles taux de E2 sont abaisses
t an t dans les grossesses pathologiques (Groupe III) que
dans les retards de croissance intra-uterine (groupe V
I'U'G'R') tandis quela constante de conversion du DHEA-
S en E2 n'est diminuee que dans le cadre du retard de
croissance (groupe V).
En conclusion, le retard de croissance resultant d'une
insuffisance placentaire est bei et bien associe ä un defaut
d'aromatisation placentaire qui contribue a expliquer en
partie les taux circulant bas en oestrogenes.
Le test au DHEA-S et le calcul de la constante de con-
version du DHEA-S en E2 par la formule mathematique
autorise une approche tres fine des troubles metaboliques
placentaires.
Mots cles: Croissance foetale, DHEA-test, insuffisance placentaire, metabolisme placentaire, Oestradiol.
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